Sanofi Myeloma Drug Sarclisa Met Primary Goal in Late-Stage Trial
07 Dezembro 2023 - 4:34AM
Dow Jones News
By Adria Calatayud
Sanofi said a late-stage clinical trial for its Sarclisa drug in
combination with other drugs met its primary goal of
progression-free survival in patients with newly diagnosed multiple
myeloma.
The French pharmaceutical company said Thursday the results came
from a planned interim analysis for efficacy in a phase 3 trial
that studies the investigational use of Sarclisa in combination
with standard-of-care bortezomib, lenalidomide and dexamethasone
against the standard of care alone.
The safety and tolerability of Sarclisa in the trial was
consistent with its established safety profile, Sanofi said.
The company said the study results will form the basis of a
future regulatory submission.
"This is the second phase 3 trial investigating Sarclisa in
newly diagnosed patients to show superiority versus standard of
care, reinforcing our belief in Sarclisa as a best-in-class
medicine," said Dietmar Berger, Sanofi's global head of
development.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
December 07, 2023 02:19 ET (07:19 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Sanofi (NASDAQ:SNY)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
